Clinical Trials Logo

Diabetes Mellitus, Type 2 clinical trials

View clinical trials related to Diabetes Mellitus, Type 2.

Filter by:

NCT ID: NCT06314061 Not yet recruiting - Diabetes Mellitus Clinical Trials

The Effect of Continuous Glucose Monitoring in Surgical Patients With Diabetes.

WARD-glucose
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The goal of this randomised controlled trial to investigate the effect of continuous glucose monitoring (CGM) compared to standard point-of-care (POC) blood glucose measurements in surgical patients with diabetes in patients. The main question it aims to answer is: • Can the use of the CGM device Dexcom G7 with real-time alerts on dysglycaemia increase the time in range for glucose levels as compared with standard monitoring with point-of-care blood glucose in surgical patients with diabetes? Participants will be asked to wear a CGM device (Dexcom G7, Dexcom Inc.) during their stay in the hospital. For patients in the intervention group, deviations of glucose levels will provide the nursing staff with alerts. All patients will receive standard care of their diabetes. The CGM device will be worn for up to 10 days or until discharge.

NCT ID: NCT06311799 Not yet recruiting - Diabetes Clinical Trials

Advancing Health Equity by Integrating Social-Clinical Models During Pregnancy

FIMPreg
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This study is being done to find out if online references to a food management program for Women, Infants, and Children (WIC) made by doctors will get more people to enroll in WIC. Women aged 18 or older who get healthcare at Geisinger, are pregnant, and have one or more heart-related health risks (high blood pressure, diabetes, or obesity) will be asked to join this study. These women need to consent to join this study. There are four groups in this study. Group 1 will get usual care with details about WIC from their doctor. Group 2 will be sent to WIC by their doctor. Group 3 will get details about WIC from their doctor and a dietitian will talk to them about heart-healthy diets and food management. Group 4 will be sent to WIC by their doctor and a dietitian will talk to them about heart-healthy diets and food management. This study will last about 18 months and will have 200 total subjects joining at about 50 per month. Each subject will be in the study for about 6 months. Subjects will be asked to complete surveys at the start and end of the study. Some subjects will also be asked about their experience in the study team after they are done.

NCT ID: NCT06310980 Not yet recruiting - Clinical trials for Diabetes Mellitus, Type 1

Pilot Study to Verify Effect of Smartpen Coordinated With Glucose Sensor.

SMARTPEN
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The Aim of this interventional study in to assess the effect of the use of a smartpen connected by an APP to continuous glucose sensors in a cohort of diabetic adolescents in not good metabolic control. Primary endpoint: time in range Secondary endpoints: other glucometrics, Hba1c, treatment satisfaction.

NCT ID: NCT06310148 Recruiting - Hypertension Clinical Trials

Evaluation of the Chronic Disease Co-Care Pilot Scheme

Start date: January 18, 2024
Phase: N/A
Study type: Interventional

The Chronic Disease Co-Care (CDCC) Pilot Scheme is initiated for early screening and management of people with hypertension (HT), pre-diabetes mellitus (pre-DM) and DM in Hong Kong. This study will evaluate the quality of care, feasibility, acceptability, effectiveness and cost-effectiveness of the Scheme. This is a 12-month cohort study among the District Health Centre (DHC) or DHC Express, healthcare providers, CDCC participants and a comparison group of 1,886 non-participants. All the person-in charge, 2 family doctors and 1 of each allied health provider from each DHC/DHC Express will be administered with the questionnaires on quality of care and costing. All CDCC participants will be included in subject characteristics, among which a convenience sample of 548 will complete a telephone survey on experience, enablement and satisfaction of the CDCC Pilot Scheme. The health outcomes of 1,886 CDCC participants and 1,886 non-participants will be compared for evaluation of effectiveness and cost-effectiveness. Participant characteristics, enablement, compliance to the standards of care, and costing of CDCC Pilot Scheme will be summarized using descriptive statistics. Differences in the proportion of patients meeting treatment targeted for HT, pre-DM and DM after 12 months will be compared by chi-squared test and logistic regressions. The incremental cost-effectiveness ratio will be evaluated by comparing with the WHO threshold. This study will inform future healthcare planning and policy for manpower and resource allocation.

NCT ID: NCT06309082 Not yet recruiting - Diabetes Mellitus Clinical Trials

Assessing Diabetic Foot Ulcer Microcirculation With High-frequency Contrast Enhanced Ultrasound

Start date: July 2024
Phase:
Study type: Observational [Patient Registry]

The objective of this observational study is to investigate and validate the utility of high-frame-rate ultrasound imaging technology for dynamic observation of the blood perfusion process at the site of ulcer wounds in real-time, focusing on patients with Diabetic Foot Ulcers (DFU). The primary research questions it seeks to address are as follows: - What are the dynamic characteristics of vascular dynamics at the site of ulcer wounds in patients with DFU under high-frame-rate ultrasound imaging? - Is High-Frequency Contrast-Enhanced Ultrasound (H-CEUS) technology feasible for effectively visualizing the microcirculation of ulcer wounds in patients with DFU? Participants will Undergo high-frame-rate ultrasound imaging for real-time observation of blood perfusion dynamics at the site of ulcer wounds. Researchers will compare ulcerated sites with normal sites to see whether the use of High-Frequency Contrast-Enhanced Ultrasound (H-CEUS) has any discernible impact on the visualization of microcirculation in ulcer wounds.

NCT ID: NCT06308549 Not yet recruiting - Type 1 Diabetes Clinical Trials

MyDiaMate For Remission Of Diabetes Distress In Type 1 Diabetes (MyREMEDY)

MyREMEDY
Start date: March 2024
Phase: N/A
Study type: Interventional

In the MyREMEDY study the investigators research whether the MyDiaMate self-help application is effective in strengthening the mental health of adults with type 1 diabetes in comparison with care as usual. The MyREMEDY study takes place in four countries: The Netherlands, United Kingdom, Spain, and Germany.

NCT ID: NCT06305377 Not yet recruiting - Clinical trials for Diabetes Mellitus, Type 1

Achieving Rapid, Safe and Sustained Glucose Control in Adolescents With Suboptimally Controlled Type 1 Diabetes Using Advanced Hybrid Closed Loop Systems

Start date: March 11, 2024
Phase:
Study type: Observational

The rational of this study is to assess if AHCL systems are able to achieve a better metabolic control (better glucometric data) after 2 weeks, 1 months. 6 months and 1 year after the start, in adolescents in not good glycaemic control.

NCT ID: NCT06305286 Not yet recruiting - Diabetes Mellitus Clinical Trials

Safety, Tolerability, and Efficacy of Immunomodulation With A in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

AT-1501 is a monoclonal antibody. Antibodies are Y-shaped proteins that are produced naturally by the subject's immune system to attack and fight foreign substances that cause illness. Monoclonal antibodies are man-made proteins manufactured to serve as substitute antibodies to fight diseases. Monoclonal antibodies can restore, enhance, or mimic (copy) the immune system's attack process; they can also tone down the immune system. AT-1501 is thought to work by dampening down the immune system so that it will be less likely to attack the transplanted cells. For other types of transplants, like kidney, a drug called a calcineurin inhibitor is usually used to prevent rejection. That class of drugs can be toxic to islet cells. AT-1501 is an experimental agent that is anticipated to prevent rejection without harming the islet cells.

NCT ID: NCT06305208 Recruiting - Obesity Clinical Trials

A UK Registry for Metabolic and Bariatric Endoscopic Interventions

UK-ENDOMAB
Start date: February 1, 2024
Phase:
Study type: Observational [Patient Registry]

In the UK alone, obesity is a major health problem with more than one quarter of adults estimated to be obese. Obesity promotes the development of many serious diseases including diabetes, heart disease, kidney disease, and increased risk of some cancers. Patients living with obesity also suffer from significant symptoms that impact their life including shortness of breath, back pain, poor mobility, and poor mental health. Traditional methods to help lose weight include low calorie diets and increased exercise. These may be effective in the short-term, but due to powerful biological mechanisms they are hard to maintain over the long-term and most individuals are unable to achieve normal weight. This means many people may need bariatric surgery that is highly effective at lowering body weight, but it is associated with complications and not all patients will want or be able to undergo surgery. This has led to the development of many new obesity treatments that are completed with an endoscope. An endoscope is a thin flexible tube that has a camera at the end. It is inserted through the mouth and into the stomach and small bowel. There are various procedures that can be done at the time of endoscopy that have been shown to be effective with a low number of side-effects. These are still relatively new compared to more traditional treatments and only a small number of doctors can perform them within the UK. Due to these limitations, the aim of this registry is to obtain real-world information on the safety and effectiveness of these procedures across the UK. The investigators hope over time this will improve the knowledge of clinicians about treating obesity with endoscopy and support future access and funding to these treatments.

NCT ID: NCT06305195 Recruiting - Diabetes Mellitus Clinical Trials

Potential Correlation Between Heart Rate Variability With Cardiovascular Risk at Different Stages of Metabolic Syndrome

Start date: August 23, 2023
Phase:
Study type: Observational

The study aims to assess the beat-to-beat Heart rate variability (HRV) in different stages of metabolic diseases, including pre-diabetic and diabetic patients, compared to non-diabetic individuals. Heart rate variability will be compared for some antidiabetic drugs used in different stages of metabolic diseases and correlated to different metabolic and inflammatory mediators.